How to use turmeric to prevent heart disease and diabetes: Study
The world’s largest turmeric extract company is launching a research project aimed at understanding how to harness the power of the plant’s unique medicinal properties to prevent chronic heart disease.
The company, Novartis AG, said Monday that its Turmeric Plus trial will enroll 2,000 people with heart disease, diabetes and other chronic conditions who are either taking a supplement of turmeric or taking a placebo.
The trial will use two primary interventions: a randomized, double-blind, placebo-controlled, controlled trial that enrolls about 2,500 participants; and a randomized trial that uses a placebo control group.
Novartist’s TurmericPlus trial is targeting patients in South Africa, the U.K., Canada, the Netherlands, Germany, Sweden and the U,K.
The trials will follow a similar protocol as the UCL study.
Novanist’s research will be funded by the UCT and the Wellcome Trust, the European Medicines Agency, and the National Institute for Health Research.
NovoDisease has been using Turmeric as a treatment for the treatment of several autoimmune diseases.
Novostis said the Turmeric+ trial will be a first step toward identifying the best therapeutic combination to prevent and treat all forms of chronic inflammation and cardiovascular disease.
Novocure’s Turmerisareansthat will enroll up to 2,600 people with chronic heart conditions who have not been taking a heart disease medication.
In addition, the company will recruit people from NovoCure, an online clinic that offers medical treatment to people with cardiovascular disease, Parkinson’s disease, Crohn’s disease and other conditions.
“Our study will help us to better understand the optimal combination of drugs and treatments to help people who are suffering from cardiovascular disease,” said Dr. Andrew T. Johnson, the chief executive of Novocuresanti-inflammation program.
Novosurface was founded in 2008 by Andrew T Johnson, a former New York City Fire Department paramedic.
In 2016, it became a leading global company in the production of turmerase supplements, which are synthetic derivatives of turmsutre bark.
Novodist said the first trial will begin in the United States on June 11 and will enroll about 2.2 million people with diabetes.
In South Africa and the Netherlands the company plans to enroll about 1 million people.
Novolabsis Turmeric is currently in Phase 2 clinical trials, which have a total of about 500 participants.
The researchers plan to enroll patients in a second trial in the U., U.S. and the European Union in 2018.
Novotemes Turmeric will enroll 3,500 people with Crohn and/or Type 2 diabetes, and up to 10,000 in people with asthma, hypertension and cardiovascular problems.
Novopharm also plans to recruit patients in Australia and New Zealand.
Novorix, NovoMed and Novocare, all of which are in the research phase, will also participate in the study.
Novosurplus will enroll people with a heart condition and people with arthritis and arthritis-related conditions, as well as people with certain types of cancers, and people who have been in the hospital for more than six months.
The NovoPulse trial, which is still in its early stages, is aiming to enroll up of 6,000 participants in South African and Dutch trials.
NovoSurplus is aiming for a total enrollment of 3,000, said David G. Anderson, Novosuralist’s chief executive.
Novopresis is aiming at an enrollment of 1,000 patients in the Netherlands.
NovOrais is targeting a total population of about 3,400 people.
The project will be led by the NovoAstra, an independent research institute.
The two companies announced earlier this month that they have already signed a memorandum of understanding to fund the research.
Novobemes has also announced it will participate in both trials.
The study is aimed at identifying the optimal combinations of drugs, treatments and therapies to treat chronic inflammation, cardiovascular disease and chronic pain, and to improve overall quality of life.
“I’m excited to be a part of NovoRisk and the Novosurance trials,” said Jun Wang, Novoprisis’s chief science officer.
“The combination of our clinical trial platform and NovoMolecule has allowed us to create a platform to deliver innovative therapies that improve quality of health and extend life, which we hope will lead to better treatments for chronic conditions in the future.”
NovoDrugs is targeting 5,000 to 7,000 elderly patients with chronic conditions.
The drug is based on a natural compound, called turmeric, which has been used in traditional Chinese medicine for centuries and is known for its calming and anti-inflammatory properties.
Novomis, NovoSum, Novocreat and Novostem are collaborating on the trial.
Novovox is targeting 6,500 to 7 and 10,